Skip to main content

Table 2 Incidence and risk factors for Pseudomonas aeruginosa community-acquired pneumonia (CAP)

From: Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia

Study/year Population/Country Prevalence of P. aeruginosa Risk factors for P. aeruginosa CAP
Aliberti et al. 2013 [2] Prospective study of two cohorts (Barcelona and Edinburgh) n = 1591 CAP patients Barcelona: 6.5% (32 cases) of these 12 cases (38%) were MDR P. aeruginosa Edinburgh: 1.6% (9 cases) of these 3 cases (30%) were MDR P. aeruginosa Nursing home; hospitalization in the previous 90 days; history of chronic lung disease
Shindo et al. 2013 [51] Prospective study of CAP and HCAP cases from Japan n = 1431 CAP 3.7% (33 cases) HCAP 8.7% (46 cases)  
Prina et al. 2015 [50] Prospective study of CAP from Spain n = 1597 4.5% P. aeruginosa Previous antibiotic use, chronic respiratory diseases, PO2/FiO2 ratio < 200
Cillóniz et al. 2016 [11] Prospective study of adult patients with CAP with definitive etiology n = 2023 4% P. aeruginosa 1.08% MDR P. aeruginosa Male sex, chronic respiratory diseases, C-reactive protein < 12.35 mg/dL, PSI IV to V Prior antibiotic treatment risk factor for MDR P. aeruginosa
Restrepo et al. 2018 [10] Multicenter, point-prevalence study of CAP patients (22 hospitals in 54 countries) n = 3193 4.2% of all population 11.3% of cases with defined etiology 2% antibiotic-resistant P. aeruginosa 1% MDR P. aeruginosa Prior pseudomonas infection/colonization, prior tracheostomy, bronchiectasis, IRVS, very severe COPD
  1. HCAP healthcare-associated pneumonia, IRVS intensive respiratory or vasopressor support, PSI pneumonia severity index, COPD: chronic obstructive pulmonary disease